The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
How Fibroblast Growth Factor 23 Works
Abstract
There is a discontinuum of hereditary and acquired disorders of phosphate homeostasis that are caused by either high or low circulating levels of the novel phosphaturic hormone fibroblastic growth factor 23 (FGF23). Disorders that are caused by high circulating levels of FGF23 are characterized by hypophosphatemia, decreased production of 1,25-dihydroxyvitamin D, and rickets/osteomalacia. On the other end of the spectrum are disorders that are caused by low circulating levels of FGF23, which are characterized by hyperphosphatemia, elevated production of 1,25-dihydroxyvitamin D, soft tissue calcifications, and hyperostosis. Knowledge of the genetic basis of these hereditary disorders of phosphate homeostasis and studies of their mouse homologues have uncovered a bone-kidney axis and new systems biology that govern bone mineralization, vitamin D metabolism, parathyroid gland function, and renal phosphate handling. Further understanding of this primary phosphate homeostatic pathway has the potential to have a significant impact on the diagnosis and treatment of disorders of bone and mineral metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · cited 5×
“Mice that are deficient in Klotho have a phenotype almost identical to that of FGF23 null mice (15), but additional findings indicate that FGF23-mediated receptor activation requires the co-factor Klotho, which seems to impart tissue specificity to FGF23 actions (12,14).”
BackgroundInfluentialAnimal Physiology: Adaptation and Environment
Schmidt‐Nielsen, K. (1962) · Cited by 2,489
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., & Yamashita, T. (2006) · Nature · doi:10.1038/nature05315 · Cited by 1,850
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Regulation of Fibroblast Growth Factor-23 Signaling by Klotho
Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Baum, M. G., Schiavi, S., Hu, M.-C., Moe, O. W., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c500457200 · Cited by 1,366
Feng, J. Q., Ward, L. M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S. I., Zhang, S., et al. (2006) · Nature Genetics · doi:10.1038/ng1905 · Cited by 1,199
Self-citationOsteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Francis, F., Hennig, S., Korn, B., Reinhardt, R., de Jong, P., Poustka, A., Lehrach, H., Rowe, P. S. N., Goulding, J. N., Summerfield, T., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-130 · Cited by 1,107
Evolution of the Fgf and Fgfr gene families
Itoh, N., & Ornitz, D. M. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.08.007 · Cited by 1,096
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E., Christenson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 837
Wang, Y., Wan, C., Deng, L., Liu, X., Cao, X., Gilbert, S. R., Bouxsein, M. L., Faugere, M.-C., Guldberg, R. E., Gerstenfeld, L. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31581 · Cited by 733
Georges, G. T., Nájera, O., Sowers, K., & Sowers, J. R. (2017) · Cardiorenal Medicine · doi:10.1159/000449476 · Cited by 680
New Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Regulation and Function of the FGF23/Klotho Endocrine Pathways
Martin, A., David, V., & Quarles, L. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00002.2011 · Cited by 594
Self-citationCytochrome P450-mediated metabolism of vitamin D
Jones, G., Prosser, D. E., & Kaufmann, M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r031534 · Cited by 503
Burosumab Therapy in Children with X-Linked Hypophosphatemia
Carpenter, T. O., Whyte, M. P., Imel, E. A., Boot, A. M., Högler, W., Linglart, A., Padidela, R., van’t Hoff, W., Mao, M., Chen, C.-Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714641 · Cited by 479
Endocrine functions of bone in mineral metabolism regulation
Quarles, L. D. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36479 · Cited by 459
Self-citationParker, B. D., Schurgers, L. J., Brandenburg, V. M., Christenson, R. H., Vermeer, C., Ketteler, M., Shlipak, M. G., Whooley, M. A., & Ix, J. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-10-201005180-00004 · Cited by 457
Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J., & Naveh-Many, T. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00360.2010 · Cited by 441
Vitamin D and immune function: an overview
Hewison, M. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s0029665111001650 · Cited by 419
Functional evolutionary history of the mouse Fgf gene family
Itoh, N., & Ornitz, D. M. (2008) · Developmental Dynamics · doi:10.1002/dvdy.21388 · Cited by 408
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367
Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A., Weber, T., Pitukcheewanont, P., Cheong, H. I., Jan de Beur, S., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3475 · Cited by 343
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification
Scialla, J. J., Lau, W. L., Reilly, M. P., Isakova, T., Yang, H.-Y., Crouthamel, M. H., Chavkin, N. W., Rahman, M., Wahl, P., Amaral, A. P., et al. (2013) · Kidney International · doi:10.1038/ki.2013.3 · Cited by 333
Ix, J. H., Katz, R., Kestenbaum, B. R., de Boer, I. H., Chonchol, M., Mukamal, K. J., Rifkin, D., Siscovick, D. S., Sarnak, M. J., & Shlipak, M. G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.040 · Cited by 324
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
Carpenter, T. O., Imel, E. A., Ruppe, M. D., Weber, T. J., Klausner, M. A., Wooddell, M. M., Kawakami, T., Ito, T., Zhang, X., Humphrey, J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72829 · Cited by 314
Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease
Quarles, L. D. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.027 · Cited by 298
Self-citationMinisola, S., Peacock, M., Fukumoto, S., Cipriani, C., Pepe, J., Tella, S. H., & Collins, M. T. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.44 · Cited by 290
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism
Quarles, L. D. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.218 · Cited by 269
Self-citationKuro-o, M. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-009-0722-7 · Cited by 256
Effects of Dietary Phosphate and Calcium Intake on Fibroblast Growth Factor-23
Vervloet, M. G., van Ittersum, F. J., Büttler, R. M., Heijboer, A. C., Blankenstein, M. A., & ter Wee, P. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04730510 · Cited by 218
“mal tubules by the sodium-phosphate exchanger (20).”
Overview of the FGF23-Klotho axis
Kuro-o, M. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1260-4 · Cited by 162
“The bone−kidney endocrine axis mediated by FGF23 and Klotho has emerged as the major regulator of phosphate homeostasis [4, 9, 24, 56–58].”
BackgroundFibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults
Panwar, B., Jenny, N. S., Howard, V. J., Wadley, V. G., Muntner, P., Kissela, B. M., Judd, S. E., & Gutiérrez, O. M. (2015) · Stroke · doi:10.1161/strokeaha.114.007489 · Cited by 65
“Discussion FGF23 is a hormone that regulates phosphorus and vitamin D metabolism.(1) In states of phosphorus excess, such as high dietary phosphorus intake or CKD, FGF23 secretion is stimulated to help maintain normal phosphorus balance by increasing urinary phosphorus excretion and reducing dietary phosphorus absorpt…”
Xie, W., Dolder, S., Siegrist, M., Wetterwald, A., & Hofstetter, W. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0129-3 · Cited by 12
Metadata
- Authors
- Liu, S., & Quarles, L. D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-06
- Volume
- 18
- Issue
- 6
- Pages
- 1637-1647
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2125079553
- Cited by
- 408
- References
- 75
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.